|Bid||72.17 x 700|
|Ask||72.40 x 200|
|Day's Range||72.12 - 72.62|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||7.87|
|Forward Dividend & Yield||2.08 (2.87%)|
|1y Target Est||N/A|
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
To receive further updates on this Gilead Sciences, Inc. (NASDAQ:GILD) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?
Gilead Sciences (GILD) is trending lower today, along with biotech in general, after Argus downgraded the stock. Analyst David Toung cut his rating on Gilead from Buy to Hold, citing concerns about increasing R&D spending at a time when sales from its blockbuster franchise is waning. Toung writes that he's concerned about the steepening decline of its hepatitis C products, as well as "flattening" HIV sales, which account for some 68% of the company's revenues.
Biotech stocks are given to high volatility, given several risks confronting the sector, namely FDA decisions, clinical trial results, competitive pressure and drugs falling off patents. Gilead Sciences, ...
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Shares of Gilead Sciences (GILD) have been on a steady downward slide since it hit a 52-week high in early September. Add to that, some investors remain unconvinced that Gilead didn’t overpay when it bought Kite Pharma for $12 billion. What do investors think of this deal and where are we?
Gilead Sciences’ (GILD) revenue rose 31% in 2015 before falling 7% in 2016. Revenue from the United States, Europe, Japan, and other countries drove revenue growth in 2015. US and…
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest batch of economic data today, including the BLS monthly Employment Situation report, the ISM Non-Manufacturing Survey and Factory Orders.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Justine Underhill from the floor of the New York Stock Exchange to discuss the latest earnings from Merck and Gilead, as well as what's in store for the biotech industry.
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.